Kodiak Sciences Inc.
2631 Hanover Street
Palo Alto
CA
94304
United States
Tel: 650281-0810
108 articles with Kodiak Sciences Inc.
-
Kodiak Sciences Announces Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
3/28/2023
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the fourth quarter ended December 31, 2022.
-
Kodiak Sciences Announces Upcoming Presentation of KSI-301 (tarcocimab tedromer) Clinical Data and Antibody Biopolymer Conjugate Development Programs at the Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting
2/9/2023
Kodiak Sciences Inc. announced today that a presentation will be made at the upcoming Angiogenesis, Exudation and Degeneration 2023 Virtual Meeting .
-
Kodiak Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Kodiak Sciences Inc. announced today that management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2023, at 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time).
-
Kodiak Sciences to Present at the Evercore ISI 5th Annual HealthCONx Conference
11/16/2022
Kodiak Sciences Inc. (NASDAQ: KOD) announced today that management will present virtually at the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022, at 9:10am Pacific Time (12:10pm Eastern Time).
-
Kodiak Sciences Announces Third Quarter 2022 Financial Results and Recent Business Highlights
11/9/2022
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended September 30, 2022.
-
Kodiak Sciences to Present at the 2022 Morgan Stanley Healthcare Conference
9/7/2022
Kodiak Sciences Inc. announced that management will present at the 2022 Morgan Stanley Healthcare Conference in New York, NY on Wednesday, September 14, 2022, at 1:05 p.m. Pacific Time.
-
Kodiak Sciences Announces Upcoming Presentations of Tarcocimab Tedromer (KSI-301) Phase 3 BEACON Study Results in Retinal Vein Occlusion (RVO)
8/18/2022
Kodiak Sciences Inc. (Nasdaq: KOD), today announced that results from the Phase 3 BEACON study in Retinal Vein Occlusion (RVO) of its investigational therapy tarcocimab tedromer (KSI-301) will be presented at two upcoming ophthalmology conferences: the 22nd EURETINA Congress in Hamburg, Germany, and the 2022 American Academy of Ophthalmology Meeting in Chicago, Illinois.
-
Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights
8/9/2022
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended June 30, 2022.
-
The week started off with a clinical bang for Verona Pharma, Kodiak, AstraZeneca and Daiichi Sankyo with wins in COPD, lung cancer and macular edema respectively.
-
Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion
8/8/2022
Kodiak Sciences Inc. announced that its BEACON Phase 3 study of tarcocimab tedromer, its novel antibody biopolymer conjugate, met the primary endpoint of non-inferior change from baseline in visual acuity at week 24 compared to aflibercept in patients with macular edema due to retinal vein occlusion.
-
Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy
8/5/2022
Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW Phase 3 clinical trial of tarcocimab tedromer (KSI-301), Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with Non-Proliferative Diabetic Retinopathy ("NPDR") without diabetic macular edema ("DME").
-
Kodiak Sciences to Present at the Jefferies Global Healthcare Conference
5/27/2022
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 9, 2022 , at 11:30 a.m.
-
Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases
5/19/2022
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, and Lonza announced today the opening of a new, custom-built, bioconjugation facility within Lonza's Ibex® Dedicate manufacturing complex in Visp (CH).
-
Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights
5/10/2022
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results for the quarter ended March 31, 2022.
-
Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences
4/29/2022
Kodiak Sciences Inc. announced that presentations of clinical study data on its investigational therapy KSI-301 will be made at two upcoming vision research conferences: the Association for Research in Vision and Ophthalmology 2022 Annual Meeting in Denver, Colorado, and Retina World Congress 2022 in Fort Lauderdale, Florida.
-
Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights
3/1/2022
Kodiak Sciences Inc. reported business highlights and financial results for the fourth quarter ended December 31, 2021.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration
2/23/2022
Kodiak Sciences Inc. announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular age-related macular degeneration.
-
Shares of Kodiak Sciences plunged nearly 70% in premarket trading after its Phase II/III study of KSI-301 failed to demonstrate non-inferior visual acuity gains compared to Regeneron’s Eylea.
-
Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema
2/3/2022
Kodiak Sciences Inc. announced that it has completed enrollment in its GLEAM and GLIMMER Phase 3 clinical trials of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in patients with diabetic macular edema.